Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) conducted an extensive review of both peer-reviewed research studies and governmental public health data, looking at the so-called “intersectionality” of factors influencing health disparities to determine that sexual and racial minority status influences cancer screening behaviors and cancer risk.
Yale Cancer Center researchers have identified novel oncogenic gene fusions in lung and pancreatic cancer, as well as sarcoma. The fusions involve RASGRF1 (an activator of RAS signaling) and promote cellular changes leading to tumor development.
Scientists at Yale Cancer Center have discovered consequences of specific gene mutations that play a role in the development of myelodysplastic syndromes and acute myeloid leukemia.
A study out of Ontario, Canada found an immediate cancer diagnosis decrease of 34% in March 2020, followed by a slow and incomplete recovery.
A study led by researchers from MD Anderson Cancer Center showed a significant overall survival benefit with ribociclib plus endocrine therapy for postmenopausal patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer.
A UTHealth-led study found increases in both men and women for several HPV-related cancers in low-income counties or those with high smoking rates. Increases were slower in the highest-income U.S. counties, or those with low smoking rates.
Vanderbilt study: World Trade Center responders at higher risk for blood cancer-associated mutations
Scientists from Vanderbilt-Ingram Cancer Center and researchers from New York determined that 9/11 first responders to the World Trade Center have increased levels of mutations that escalate their risk for blood cancers or cardiovascular disease.
Researchers from NYU Grossman School of Medicine and NYU’s Laura and Isaac Perlmutter Cancer Center found that amyloid beta, a protein known to build-up in the brains of Alzheimer’s patients, helps melanoma cells thrive when they have spread to the brain. The study authors focused on melanoma because it metastasizes to the brain in 40% of patients with stage IV disease.
A COVID-19 investigational vaccine, developed by City of Hope scientists and now licensed to GeoVax Labs Inc., produced a robust neutralizing antibody and T cell response against SARS-CoV-2 with no significant side effects in a phase I clinical trial led by John Zaia, Aaron D. Miller and Edith Miller Chair for Gene Therapy.
Boston Cell Standards has established the Consortium for Analytic Standardization in Immunohistochemistry. The organization is led by an international panel of pathologists and scientists focused on improving patient immunohistochemistry test accuracy and reproducibility.
